Ishida, Princess M.

HRN: 17-72-85  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/30/2025
CEFUROXIME 750MG (VIAL)
07/30/2025
08/06/2025
IV
750mg
Q8
Abrasions
Checking Initial Appropriateness 

 Indication:  Empiric    Type of Infection:  Skin & Soft Tissue    Compliance to guidelines: Compliant To Guidelines